Compare · ACON vs ELV
ACON vs ELV
Side-by-side comparison of Aclarion Inc. (ACON) and Elevance Health Inc. (ELV): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ACON and ELV operate in Medical Specialities (Health Care), so they compete in similar markets.
- ELV is the larger of the two at $92.91B, about 16503.7x ACON ($5.6M).
- Both names hit the wire about 3 times in the past 4 weeks.
- ELV has more recent analyst coverage (23 ratings vs 0 for ACON).
- Company
- Aclarion Inc.
- Elevance Health Inc.
- Price
- -
- -
- Market cap
- $5.6M
- $92.91B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NYSE
- IPO
- 2022
- News (4w)
- 3
- 3
- Recent ratings
- 0
- 23
Aclarion Inc.
Aclarion, Inc., a healthcare technology company, develops software application for magnetic resonance spectroscopy (MRS) in the United States. It offers NOCISCAN-LS Post-Processor suite comprising NOCICALC-LS that receives and processes the acquired disc MRS data to calculate levels of degenerative pain biomarkers; and NOCIGRAM-LS, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was founded in 2008 and is based in San Mateo, California.
Elevance Health Inc.
Elevance Health Inc. operates as a health benefits company. It supports consumers, families, and communities across the entire care journey connecting to the care, support, and resources to lead healthier lives. It serves approximately 118 million people through a portfolio of medical, digital, pharmacy, behavioral, clinical, and care solutions. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health Inc. in June 2022. Elevance Health Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.
Latest ACON
- Aclarion to Present at the 20th Annual LD Micro Main Event
- Aclarion Broadens CLARITY Trial Enrollment Criteria to Accelerate Enrollment
- Aclarion Welcomes NYU Langone Health to CLARITY Trial Network, Now Enrolling at Eleven Sites
- Aclarion Announces Addition of University of Arizona College of Medicine – Phoenix as CLARITY Trial Site
- Director Williams Amanda M bought $15,990 worth of shares (5,857 units at $2.73), increasing direct ownership by 29% to 25,857 units (SEC Form 4)
- CFO Gould Gregory A bought $24,500 worth of shares (10,000 units at $2.45), increasing direct ownership by 20% to 60,000 units (SEC Form 4)
- Chief Executive Officer Ness Brent bought $12,091 worth of shares (5,234 units at $2.31), increasing direct ownership by 5% to 111,534 units (SEC Form 4)
- Director Bond Ryan bought $50,059 worth of shares (21,122 units at $2.37), increasing direct ownership by 38% to 76,122 units (SEC Form 4)
- Director Wesemann William bought $5,031 worth of shares (2,150 units at $2.34), increasing direct ownership by 10% to 23,713 units (SEC Form 4)
- Director Neal David K bought $18,000 worth of shares (7,500 units at $2.40), increasing direct ownership by 33% to 30,002 units (SEC Form 4)
Latest ELV
- SEC Form 4 filed by Elevance Health Inc.
- Elevance Health to Hold Conference Call and Webcast to Discuss Third Quarter 2026 Results on October 21, 2026
- Elevance Health’s Affiliated 2027 Medicare Advantage Plans Advance Stability, Choice and More Coordinated Support
- Elevance Health Inc. filed SEC Form 8-K: Regulation FD Disclosure
- EVP & Chief Legal Officer Wessling Erin M covered exercise/tax liability with 349 shares, decreasing direct ownership by 5% to 7,230 units (SEC Form 4)
- EVP & Chief HR Officer Craig Ryan R covered exercise/tax liability with 144 shares, decreasing direct ownership by 2% to 6,530 units (SEC Form 4)
- Elevance Health Strengthens Connected Cancer Care Model to Support Consumers Through Their Health Journey
- Director Peru Ramiro G bought $366,050 worth of shares (1,000 units at $366.05), increasing direct ownership by 10% to 10,908 units (SEC Form 4)
- President and CEO Boudreaux Gail bought $1,002,230 worth of shares (2,725 units at $367.79), increasing direct ownership by 2% to 171,976 units (SEC Form 4)
- SEC Form 10-Q filed by Elevance Health Inc.